News | Which Medical Device

SIR-Spheres Y-90 Resin Microspheres Are a Well-Tolerated Alternative to Standard Therapies for Inoperable Primary Liver Cancer, New UK NICE Medtech Innovation Briefing Says Read more

Vivasure Medical, a company out of Galway, Ireland, landed CE Mark approval to introduce in Europe its fully absorbable percutaneous vascular closure device for use in large vessel femoral arteriotomies following transcatheter procedures. Read more

Contego Medical announced the European commercialisation of the Paladin carotid postdilation angioplasty balloon for patients undergoing carotid stenting procedures.  Read more

A new analysis of the MORE data on 606 mCRC patients treated with SIR-Spheres Y-90 resin microspheres at 11 US medical centres, published late last year in Clinical Colorectal Cancer, confirms that patient age is not a barrier to appropriate treatment with the product, Sirtex has reported.  Read more

Healio reports that Bard's balloon-expandable vascular stent was useful in children with CV lesions and allowed implantation in distal and tortuous lesions, but it was associated with early fractures, according to new data.  Read more

PRNewswire reported that Essential Medical, Inc., a privately held medical device company, announced that it has successfully completed additional clinical studies using its MANTA 14F Large Bore Vascular Closure device, a revolutionary vascular closure device designed to seal both 14F and 18F large bore femoral punctures. Read more

PRNewswire reported that Essential Medical, Inc., a privately held medical device company, announced that it has received CE mark approval for X-Seal, a new vascular closure device with superior handling and closure features.  Read more

Sirtex Medical Limited is pleased to announce that the American Society for Clinical Oncology (ASCO) has published the SIRFLOX Study abstract as part of the 2015 Annual Meeting Abstracts.  Read more

Newly published European Society for Medical Oncology (ESMO) clinical guidelines for the treatment of metastatic colorectal cancer (mCRC) endorse radioembolisation, specifically with Yttrium-90 resin microspheres, as a clinically proven technology to \"prolong time to liver tumour progression\" in mCRC patients who have failed to respond to available chemotherapy options. Read more

Combined data from more than 1,000 patients being collected to assess overall survival (OS) benefit of adding first-line SIR-Spheres? Y-90 resin microspheres treatment to a current chemotherapy regimen for inoperable metastatic colorectal cancer (mCRC)  Read more

In the first-line treatment of non-resectable metastatic colorectal cancer, the preliminary analysis of the SIRFLOX study results does not show a statistically significant improvement in overall progression-free survival ie, at any site. However, the study does show a statistically significant improvement in progression-free survival in the liver. Read more

In the first-line treatment of non-resectable metastatic colorectal cancer, the preliminary analysis of the SIRFLOX study results does not show a statistically significant improvement in overall progression-free survival ie, at any site. However, the study does show a statistically significant improvement in progression-free survival in the liver. Read more

Sirtex Medical Limited has announced it completed patient enrolment in FOXFIRE and FOXFIRE Global, two large-scale multi-centre clinical trials that combine liver-directed radiation therapy with SIR-Spheres Y-90 resin microspheres to a chemotherapy regimen in over 560 inoperable metastatic colorectal cancer (mCRC) patients. Read more

Sirtex Medical Limited (ASX: SRX) is pleased to report the preliminary results of its SIRFLOX clinical study. Based on the preliminary analysis just completed, the primary endpoint of the SIRFLOX study was not achieved. The preliminary analysis shows that adding SIR-Spheres? Y-90 resin microspheres to a current first-line systemic chemotherapy regimen for the treatment of non-resectable metastatic colorectal cancer (mCRC) does not result in a statistically significant improvement in the overall Progression-Free Survival (PFS). Overall PFS measures progression of existing tumours and/or the development of new tumours in any organ or body site. Read more

SARAH Study completes enrollment for HCC trial, results expected in 2016 Read more

FOXFIRE UPDATE Recruitment to FOXFIRE has now closed. Thank you to all of the sites who contributed in recruiting patients to the trial. The final total was 364; this is a fantastic achievement and will allow the overall survival statistic to be answered. Read more

Osteoarthritis (OA) is the most common joint disease worldwide. According to the American College of Rheumatology, approximately 70 % of people over the age of 70 have radiographic evidence of osteoarthritis, though only half develop symptoms(1). Read more

Osteoarthritis (OA) is the most common joint disease worldwide. According to the American College of Rheumatology, approximately 70 % of people over the age of 70 have radiographic evidence of osteoarthritis, though only half develop symptoms(1). Read more

Osteoarthritis (OA) is the most common joint disease worldwide. According to the American College of Rheumatology, approximately 70 % of people over the age of 70 have radiographic evidence of osteoarthritis, though only half develop symptoms(1).  Read more

Osteoarthritis (OA) is the most common joint disease worldwide. According to the American College of Rheumatology, approximately 70 % of people over the age of 70 have radiographic evidence of osteoarthritis, though only half develop symptoms(1).  Read more